Symbols

STOK

Stoke Therapeutics·NASDAQ

--(--)

STOK Profile

Stoke Therapeutics, Inc.

A biotech company that develops antisense oligonucleotide medicines to target RNA splicing to enhance gene expression

Industry

Biological Technology

Established Date

Listing Date

06/19/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

170

Fiscal Year Ends

12-31

Website

www.stoketherapeutics.com

Security Type

Common stock

Office address

45 Wiggins Avenue, Bedford, MA 01730

Business

Introduction

Stoke Therapeutics, Inc., was founded in June 2014 and was incorporated under the laws of the State of Delaware. The company is a late-stage clinical enterprise focused on up-regulating protein expression through RNA drugs to address the underlying causes of serious diseases. With its proprietary TANGO (Targeted Enhanced Nuclear Gene Output) technology platform, the company is committed to developing antisense oligonucleotide drugs to selectively restore protein levels. Its leading drug in development, zorebunersen (STK-001), is a therapy with potential for disease modification and is currently in late-stage clinical trials for the treatment of severe progressive hereditary epilepsy, Dravet syndrome. The company focuses on diseases related to insufficiency of single dose as well as central nervous system and ophthalmological diseases, and its technology concept has been proof-of-concept in multiple biological systems. Led by a management team with extensive experience in the fields of human genetics, RNA regulation and rare disease drug development, the company continues to advance its pipeline of innovative therapies.